Collection of allogeneic peripheral blood stem cells

Bailliere's Best Practice in Clinical Haematology

Volumn 12, Issue 1-2, 1999, Pages 41-55

  Körbling, Martin ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic blood stem cell transplantation; Apheresis; Flt3 ligand; G CSF; Stem cell mobilization

Indexed keywords

CD34 ANTIGEN; CYTOKINE; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 1;

ALLOGENIC BONE MARROW TRANSPLANTATION; APHERESIS; BONE PAIN; FATIGUE; HEADACHE; HUMAN; HUMAN CELL; LYMPHATIC SYSTEM TUMOR; MOBILIZATION; NAUSEA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; SPLEEN RUPTURE;

EID: 0032737149     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0006     Document Type: Article

References (64)

1. dim) and lymphoid subsets, and possible predictors of engraftment and GVHD. Blood 1995; 86: 2842-2848.
2. + blood cells. Blood 1995; 86: 2500-2508.
3. Molineux G, Pojda Z, Hampson IN et al. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 1990; 76: 2153-2158.
4. Bensinger WI, Price TH, Dale DC et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-1888.
5. Caspar CB, Seger RA, Burger J & Gmur J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993; 81: 2866-2871.
6. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
7. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-282.
8. Ali SM, Brown RA, Adkins DR et al. Analysis of lymphocyte subsets and peripheral blood progenitor cells (PBPC) in apheresis products from normal donors mobilized with either G-CSF or concurrent G-CSF and GM-CSF. Blood 1997; 80 (supplement 1): 564a.
9. Molineux G, McCrea C, Yan XQ et al. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 1997; 89: 3998-4004.
10. Lebsack ME, McKenna HJ, Hoek JA et al. Safety of FLT3 ligand in healthy volunteers. Blood 1997; 90 (supplement 1): 170a.
11. Lynch DH, Andreasen A, Maraskovsky E et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nature Medicine 1997; 3: 625-631.
12. Weaver CH, Longin K, Buckner CD & Bensinger W. Lymphocyte content in peripheral blood mono-nuclear cells collected after administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplantation 1994; 13: 411.
13. Prosper F, Stroncek D & Verfaillie CM. Mobilization of LTC-IC in normal donors treated with G-CSF: phenotypic analysis of mobilized PBSC. Blood 1995; 86 (supplement 1): 464a.
14. Fujisaki T, Otsuka T, Harada M et al. Granulocyte colony-stimulating factor mobilizes primitive hematopoietic stem cells in normal individuals. Bone Marrow Transplantation 1995; 16: 57-62.
15. + blood cells. Blood 1995; 86: 2500-2508.
16. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte-stimulating factor. Blood 1994; 84: 2795-2801.
17. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
18. Tanaka R, Matsudaira T, Tanaka I et al. Kinetics and characteristics of peripheral blood progenitor cells mobilized by G-CSF in normal healthy volunteers. Blood 1994; 84 (supplement 1): 541a.
19. Dreger P, Haferlach T, Eckstein V et al. Filgrastim-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics and mobilization, and composition of the graft. British Journal of Haematology 1994; 87: 609.
20. + cell counts. Blood 1994; 84 (supplement 1): 541a.
21. Höglund M, Smedmyr B, Simonsson B et al. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplantation 1996; 18: 19-27.
22. Stroncek D, Clay M, Lennon S et al. Collection of two blood progenitor cell components from healthy donors. Blood 1996; 88 (supplement 1): 396a.
23. Waller CF, Bertz H, Wenger MK et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplantation 1996; 18: 279-283.
24. Stiff P, Malhotra D, Bayer R et al. High dose G-CSF improves stem cell mobilization and collection compared to standard doses in patients with ovarian cancer which leads to a decrease in delayed platelet engraftment following stem cell transplants. Blood 1997; 80 (supplement 1): 591a.
25. + cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507-512.
26. Anderlini P, Przepiorka D, Champlin R & Körbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88: 2819-2825.
27. Becker PS, Wagle M, Matous S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biology of Blood and Marrow Transplantation 1997; 3: 45-49.
28. Bonilla MA, Dale D, Zeidler C et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. British Journal of Haematology 88: 723-730.
29. Sakamaki S, Matsunaga T, Hirayama Y et al. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432-1433 (letter).
30. Hasenclever D & Sextro M. Safety of alloPBSCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplantation 1996; 17 (supplement 2): S28-S30.
31. Gilman P, Jackson D & Guild H. Congenital agranulocytosis: prolonged survival and terminal acute leukemia. Blood 1970; 36: 576-585.
32. de Planque MM, Bacigalupo A, Würsch A et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. British Journal of Haematology 1989; 73: 121-126.
33. Russell N, Gratwohl A & Schmitz N. The place of blood stem cells in allogeneic transplantation. British Journal of Haematology 1996; 93: 747-753.
34. Lane T. Allogeneic marrow reconstitution using peripheral blood stem cells: the dawn of a new era. Transfusion 1996; 36: 585-589.
35. Körbling M, Przepiorka D, Gajewski J et al. With first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? Blood 1995; 86: 1235 (letter).
36. Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903-908.
37. + progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. British Journal of Haematology 1996; 93: 940-942.
38. Kanold J, Rapatel C, Berger M et al. Use of G-CSF alone to mobilize peripheral blood stem cells for collection from children. British Journal of Haematology 1994; 88: 633-635.
39. Takaue Y, Kawano Y, Abe T et al. Collection and transplantation of peripheral blood stem cells in very small children weighing 20 kg or less. Blood 1995; 86: 372-380.
40. Körbling M, Chan KW, Anderlini P et al. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplantation 1996; 18: 885-890.
41. Standards for Blood Banks and Transfusion Services (18th edition), edited by J.E. Menitove, American Association of Blood Banks Publications, Bethesda, MD, 1997.
42. Standards for Hematopoietic Progenitor Cell Collection, Processing & Transplantation. Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT), 1st edn, North America, 1996.
43. Stroncek D, Clay M, Lennon S et al. Neutropenia following the collection of granulocyte colony-stimulating factor mobilized blood progenitor cell components is due to the collection of progenitor cells. Blood 1996; 88 (supplement 1): 396a.
44. Malachowski ME, Comenzo RL, Hillyer CD et al. Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 1992; 32: 732-735.
45. Comenzo RI, Malachowski ME, Miller KB et al. Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma. Transfusion 1992; 32: 729-731.
46. Passos-Coelho JL, Braine HG, Wright SK et al. Large volume leukapheresis using regional citrate anti-coagulation to collect peripheral blood progenitor cells. Journal of Hematotherapy 1995; 4: 11-19.
47. Hillyer CD, Tiegerman KO & Berkman EM. Increase in circulating colony-forming units-granulocyte-macrophage during large-volume leukapheresis: evaluation of a new cell separator. Transfusion 1991; 31: 327-332.
48. Körbling M, Mirza N, Fischer H et al. Circulating blood as a source of hematopoietic stem cells for allogeneic transplantation in 112 HLA-identical patients with advanced hematologic malignancies and solid tumors. Transfusion (submitted for publication).
49. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. Journal of Clinical Oncology 1994; 12: 28-36.
50. + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
51. Russell N, Gratwohl A & Schmitz N. The place of blood stem cells in allogeneic transplantation. British Journal of Haematology 1996; 93: 747-753.
52. Anderlini P, Lauppe J, Przepiorka D et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. British Journal of Haematology 1997; 96: 415-417.
53. - progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplantation 1996; 18: 1073-1079.
54. Martinez C, Urbano-Ispizua A, Rozman C et al. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Annals of Hematology 1996; 72: 269-272.
55. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
56. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
57. Zeng D, Dejbakhsh-Jones S & Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.
58. +) in the blood of normal donors. Blood 1997; 89: 2586-2595.
59. Pan L, Delmonte J Jr, Jalonen CK & Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft versus host disease. Blood 1995; 86: 4422-4429.
60. 1 integrin expression and function. Blood 1997; 90 (supplement 1): 260a.
61. Verfaillie C, Hurley R, Bhatia R et al. Role of bone marrow matrix in normal and abnormal hematopoiesis. Critical Reviews in Oncology and Hematology 1994; 16: 201-224.
62. Simmons PJ, Masinovsky B, Longenecker BM et al. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992; 80: 388-395.
63. 4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proceedings of the National Academy of Sciences of the USA 1995; 92: 9647-9651.
64. 4 integrin. Proceedings of the National Academy of Sciences of the USA 1993; 90: 9374-9378.